Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of sonlicromanol in adults with mitochondrial disease due to the m.3243A>G MT-TL1 mutation
NL-OMON52925Phase 2Completed
- Sponsor
- Khondrion
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonlicromanol in Mitochondriopathy, sponsored by Khondrion. Primary endpoints: Treatment-emergent adverse events, Vital signs changes and 2 more. Started Sep 2021; status: completed.
02
Drugs
sonlicromanol
03
Conditions
Mitochondriopathy
Beyond the preview
Go deeper on NL-OMON52925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52925.